276 related articles for article (PubMed ID: 7555036)
21. Rifaximin treatment in hepatic encephalopathy.
Bass NM; Mullen KD; Sanyal A; Poordad F; Neff G; Leevy CB; Sigal S; Sheikh MY; Beavers K; Frederick T; Teperman L; Hillebrand D; Huang S; Merchant K; Shaw A; Bortey E; Forbes WP
N Engl J Med; 2010 Mar; 362(12):1071-81. PubMed ID: 20335583
[TBL] [Abstract][Full Text] [Related]
22. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
23. [Role of rifaximin in the treatment of hepatic encephalopathy].
Sanchez-Delgado J; Miquel M
Gastroenterol Hepatol; 2016 Apr; 39(4):282-92. PubMed ID: 26545947
[TBL] [Abstract][Full Text] [Related]
24. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.
Pedretti G; Calzetti C; Missale G; Fiaccadori F
Ital J Gastroenterol; 1991 May; 23(4):175-8. PubMed ID: 1751811
[TBL] [Abstract][Full Text] [Related]
25. [Prevention and treatment of hepatic encephalopathy].
Sivolap YP
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
[TBL] [Abstract][Full Text] [Related]
26. Minimal hepatic encephalopathy in cirrhosis- how long to treat?
Goyal O; Sidhu SS; Kishore H
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):115-122. PubMed ID: 28051800
[TBL] [Abstract][Full Text] [Related]
27. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
28. Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis.
Cheng J; Chen Y; Cao W; Zuo G
Medicine (Baltimore); 2021 Dec; 100(51):e28232. PubMed ID: 34941089
[TBL] [Abstract][Full Text] [Related]
29. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
Paik YH; Lee KS; Han KH; Song KH; Kim MH; Moon BS; Ahn SH; Lee SJ; Park HJ; Lee DK; Chon CY; Lee SI; Moon YM
Yonsei Med J; 2005 Jun; 46(3):399-407. PubMed ID: 15988813
[TBL] [Abstract][Full Text] [Related]
30. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
Kang SH; Lee YB; Lee JH; Nam JY; Chang Y; Cho H; Yoo JJ; Cho YY; Cho EJ; Yu SJ; Kim MY; Kim YJ; Baik SK; Yoon JH
Aliment Pharmacol Ther; 2017 Nov; 46(9):845-855. PubMed ID: 28836723
[TBL] [Abstract][Full Text] [Related]
31. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.
Mas A; Rodés J; Sunyer L; Rodrigo L; Planas R; Vargas V; Castells L; Rodríguez-Martínez D; Fernández-Rodríguez C; Coll I; Pardo A;
J Hepatol; 2003 Jan; 38(1):51-8. PubMed ID: 12480560
[TBL] [Abstract][Full Text] [Related]
32. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.
Williams R; Bass N
Rev Gastroenterol Disord; 2005; 5 Suppl 1():S10-8. PubMed ID: 15976747
[TBL] [Abstract][Full Text] [Related]
33. Rifaximin for treatment of hepatic encephalopathy.
Maclayton DO; Eaton-Maxwell A
Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
[TBL] [Abstract][Full Text] [Related]
34. Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment.
Fritz MK; Mangino AA; Hunt TV; Pitcock CT; Dugan AJ; Karri K; Yarra P
Ann Pharmacother; 2023 Aug; 57(8):899-906. PubMed ID: 36367093
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.
Williams R; James OF; Warnes TW; Morgan MY
Eur J Gastroenterol Hepatol; 2000 Feb; 12(2):203-8. PubMed ID: 10741936
[TBL] [Abstract][Full Text] [Related]
36. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
[TBL] [Abstract][Full Text] [Related]
37. Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin.
Sousa AL; Salgado P; Alves JE; Silva S; Ferreira S; Magalhães M
Tremor Other Hyperkinet Mov (N Y); 2019; 9():. PubMed ID: 31413898
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy for the treatment and prevention of hepatic encephalopathy.
Mohammad RA; Regal RE; Alaniz C
Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
[TBL] [Abstract][Full Text] [Related]
39. Rifaximin for the treatment of hepatic encephalopathy.
Lawrence KR; Klee JA
Pharmacotherapy; 2008 Aug; 28(8):1019-32. PubMed ID: 18657018
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic Performance of the ICD-10 Code K76.82 for Hepatic Encephalopathy in Patients With Cirrhosis.
Ozturk NB; Jamil LH; Tapper EB
Am J Gastroenterol; 2024 Feb; 119(2):364-366. PubMed ID: 37830544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
